/   itc.company   / English  

2019-11-08 22:05:57

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Wednesday, November 13, to review and discuss the marketing application from Boehringer Ingelheim seeking approval to use Jardiance (empagliflozin) to treat adults with type 1 diabetes.

Jardiance is currently approved in the U.S. for type 2 diabetes.

Meeting materials

Related ticker: Eli Lilly (LLY +0.6%)

seekingalpha.com Sa Editor Douglas W. House
jardiance lilly seekingalpha https comnews3517323 wednesday advisory application marketing discuss review november

User comments